Download MendeleyDiscovery of AB680: A Potent and Selective Inhibitor of CD73.
Lawson, K.V., Kalisiak, J., Lindsey, E.A., Newcomb, E.T., Leleti, M.R., Debien, L., Rosen, B.R., Miles, D.H., Sharif, E.U., Jeffrey, J.L., Tan, J.B.L., Chen, A., Zhao, S., Xu, G., Fu, L., Jin, L., Park, T.W., Berry, W., Moschutz, S., Scaletti, E., Strater, N., Walker, N.P., Young, S.W., Walters, M.J., Schindler, U., Powers, J.P.(2020) J Med Chem 63: 11448-11468
- PubMed: 32614585
- DOI: https://doi.org/10.1021/acs.jmedchem.0c00525
- Primary Citation of Related Structures:
6Z9B, 6Z9D - PubMed Abstract:
Extracellular adenosine (ADO), present in high concentrations in the tumor microenvironment (TME), suppresses immune function via inhibition of T cell and NK cell activation. Intratumoral generation of ADO depends on the sequential catabolism of ATP by two ecto-nucleotidases, CD39 (ATP → AMP) and CD73 (AMP → ADO). Inhibition of CD73 eliminates a major pathway of ADO production in the TME and can reverse ADO-mediated immune suppression. Extensive interrogation of structure-activity relationships (SARs), structure-based drug design, and optimization of pharmacokinetic properties culminated in the discovery of AB680, a highly potent ( K i = 5 pM), reversible, and selective inhibitor of CD73. AB680 is further characterized by very low clearance and long half-lives across preclinical species, resulting in a PK profile suitable for long-acting parenteral administration. AB680 is currently being evaluated in phase 1 clinical trials. Initial data show AB680 is well tolerated and exhibits a pharmacokinetic profile suitable for biweekly (Q2W) iv-administration in human.
Organizational Affiliation:
Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States.
